SCHEDULE 13G/A: Paradigm BioCapital Discloses 2.3% Stake in Cogent Biosciences

Paradigm BioCapital Advisors LP and related entities have reported a 2.3% beneficial ownership stake in Cogent Biosciences, Inc. as of September 30, 2025.

Summary

• Paradigm BioCapital Advisors LP, Paradigm BioCapital Advisors GP LLC, and Senai Asefaw, M.D. each report beneficial ownership of 3,156,398 shares of Cogent Biosciences, Inc. common stock, representing 2.3% of the class.
• This aggregate ownership includes shares held by Paradigm BioCapital International Fund Ltd. and one or more separately managed accounts managed by Paradigm BioCapital Advisors LP.
• Paradigm BioCapital International Fund Ltd. directly beneficially owns 2,786,647 shares of Cogent Biosciences, Inc. common stock, representing 2.0% of the class.
• The beneficial ownership is reported as of September 30, 2025, the date of the event requiring this filing.
• The percentages of beneficial ownership are based on 139,827,662 shares of Common Stock outstanding as of September 30, 2025, as reported by Cogent Biosciences, Inc. in its Form 10-Q filed with the SEC on November 7, 2025.
• The reporting persons certify that the securities were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of Cogent Biosciences, Inc.

Sentiment

Score: 5

Explanation: The filing is a routine disclosure of beneficial ownership and does not inherently convey positive or negative sentiment regarding the issuer's performance or prospects. It simply updates an investor's stake.

Future Outlook

NA

Management Comments

• To the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under Rule 14a-11.

Industry Context

This filing is a routine disclosure of beneficial ownership by an investment firm in a biotechnology company. It does not provide specific industry context or trends beyond the fact that Paradigm BioCapital invests in the biotech sector.

Stakeholder Impact

• Shareholders: Provides transparency regarding a significant institutional investor's stake, which is currently below the 5% threshold for more active disclosure requirements (though this is an amendment to a 13G, implying prior filings). The certification disclaiming intent to control may reassure some investors.

Key Dates

Keywords

Cogent Biosciences, Paradigm BioCapital, Beneficial Ownership, SEC Filing, Schedule 13G, Common Stock, Biotechnology, Investment Stake